Industry Trend Analysis - Obesity Rates Will Ensure High Demand For Chronic Disease Treatments - APR 2017
BMI View : Unmet health needs for patients wh o are obes e, and the condition ' s associated chronic disease s, will continue to remain a theme in the MENA region. The rise of obesity-related non-communicable diseases highlights the need to improve health awareness , and implement preventative strategies at the national level. This will provide opportunities for multinational drugmakers to partner with authorities with the goal of meeting the large underlying demand for chronic disease treatments in the region. Critically , multinational pharmaceutical firms will have to adopt country-specific strategies given the differences in healthcare access and epidemiological profiles between each country.
Obesity will be a leading public healthcare challenge in markets within the Middle East and North Africa (MENA) region. The growing burden of non-communicable diseases (NCDs) echoes the overwhelming obesity epidemic throughout the region. Whilst traditional policy responses have been weak and focused on simply treating obesity ( see ' Significant Obesity Burden To Perpetuate Policy Decisions ', February 09 2017), there is an urgent need to implement more preventative healthcare measures for obesity and its associated illnesses. For pharmaceutical firms, they will need to ensure the risk of such related diseases is properly communicated to governments and consumers in order to maximise potential revenue-earning opportunities.
Obesity: A Significant Risk Factor For Chronic Diseases
|Chronic Conditions A Significant Burden|
|MENA: Leading Non-Communicable Diseases, DALYs|
|DALYs = Disability-Adjusted Life Years. Source: BMI's Disease Database|